198 related articles for article (PubMed ID: 7525961)
1. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase.
Moore WM; Webber RK; Jerome GM; Tjoeng FS; Misko TP; Currie MG
J Med Chem; 1994 Nov; 37(23):3886-8. PubMed ID: 7525961
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of nitric oxide synthases and cellular nitric oxide formation by N6-iminoethyl-L-lysine and N5-iminoethyl-L-ornithine.
Wolff DJ; Lubeskie A; Gauld DS; Neulander MJ
Eur J Pharmacol; 1998 Jun; 350(2-3):325-34. PubMed ID: 9696424
[TBL] [Abstract][Full Text] [Related]
3. L-N6-(1-iminoethyl)-lysine potently inhibits inducible nitric oxide synthase and is superior to NG-monomethyl-arginine in vitro and in vivo.
Stenger S; Thuring H; Rollinghoff M; Manning P; Bogdan C
Eur J Pharmacol; 1995 Dec; 294(2-3):703-12. PubMed ID: 8750736
[TBL] [Abstract][Full Text] [Related]
4. L-N6-(1-iminoethyl)-lysine (L-NIL) but not S-methylisothiourea sulphate (SMT) displays selectivity towards NOS-2.
Chłopicki S; Olszanecki R; Jakubowski A; Lomnicka M; Gryglewski RJ
Pol J Pharmacol; 1999; 51(5):443-7. PubMed ID: 10817546
[TBL] [Abstract][Full Text] [Related]
5. 2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo.
Faraci WS; Nagel AA; Verdries KA; Vincent LA; Xu H; Nichols LE; Labasi JM; Salter ED; Pettipher ER
Br J Pharmacol; 1996 Nov; 119(6):1101-8. PubMed ID: 8937711
[TBL] [Abstract][Full Text] [Related]
6. Structural requirements for human inducible nitric oxide synthase substrates and substrate analogue inhibitors.
Grant SK; Green BG; Stiffey-Wilusz J; Durette PL; Shah SK; Kozarich JW
Biochemistry; 1998 Mar; 37(12):4174-80. PubMed ID: 9521739
[TBL] [Abstract][Full Text] [Related]
7. Selective iNOS inhibition attenuates acetylcholine- and bradykinin-induced vasoconstriction in lipopolysaccharide-exposed rat lungs.
Fischer LG; Horstman DJ; Hahnenkamp K; Kechner NE; Rich GF
Anesthesiology; 1999 Dec; 91(6):1724-32. PubMed ID: 10598616
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of inducible nitric oxide synthase in persistent pain.
Budziñski M; Misterek K; Gumulka W; Dorociak A
Life Sci; 2000; 66(4):301-5. PubMed ID: 10665981
[TBL] [Abstract][Full Text] [Related]
9. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase.
Reilly CM; Farrelly LW; Viti D; Redmond ST; Hutchison F; Ruiz P; Manning P; Connor J; Gilkeson GS
Kidney Int; 2002 Mar; 61(3):839-46. PubMed ID: 11849435
[TBL] [Abstract][Full Text] [Related]
10. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase.
Connor JR; Manning PT; Settle SL; Moore WM; Jerome GM; Webber RK; Tjoeng FS; Currie MG
Eur J Pharmacol; 1995 Jan; 273(1-2):15-24. PubMed ID: 7537678
[TBL] [Abstract][Full Text] [Related]
11. Selective iNOS inhibition prevents hypotension in septic rats while preserving endothelium-dependent vasodilation.
Strunk V; Hahnenkamp K; Schneuing M; Fischer LG; Rich GF
Anesth Analg; 2001 Mar; 92(3):681-7. PubMed ID: 11226101
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury.
Chatterjee PK; Patel NS; Kvale EO; Cuzzocrea S; Brown PA; Stewart KN; Mota-Filipe H; Thiemermann C
Kidney Int; 2002 Mar; 61(3):862-71. PubMed ID: 11849439
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of inducible nitric oxide synthase exacerbates erosive joint disease.
McCartney-Francis NL; Song X; Mizel DE; Wahl SM
J Immunol; 2001 Feb; 166(4):2734-40. PubMed ID: 11160339
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological characterization of L-N(6)-(1-iminoethyl)lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitor.
Hallinan EA; Tsymbalov S; Dorn CR; Pitzele BS; Hansen DW; Moore WM; Jerome GM; Connor JR; Branson LF; Widomski DL; Zhang Y; Currie MG; Manning PT
J Med Chem; 2002 Apr; 45(8):1686-9. PubMed ID: 11931623
[TBL] [Abstract][Full Text] [Related]
15. L-N-iminoethyl-lysine after experimental brain trauma attenuates cellular proliferation and astrocyte differentiation.
Arnberg F; Gahm C; Mathiesen T
Acta Neurochir (Wien); 2012 Apr; 154(4):681-7. PubMed ID: 22297397
[TBL] [Abstract][Full Text] [Related]
16. Examination of N-hydroxylation as a prerequisite mechanism of nitric oxide synthase inactivation.
Maurer TS; Pan J; Booth BP; Kalman TI; Fung HL
Bioorg Med Chem Lett; 2000 May; 10(10):1077-80. PubMed ID: 10843221
[TBL] [Abstract][Full Text] [Related]
17. Evidence for peroxynitrite formation in renal ischemia-reperfusion injury: studies with the inducible nitric oxide synthase inhibitor L-N(6)-(1-Iminoethyl)lysine.
Walker LM; Walker PD; Imam SZ; Ali SF; Mayeux PR
J Pharmacol Exp Ther; 2000 Oct; 295(1):417-22. PubMed ID: 10992009
[TBL] [Abstract][Full Text] [Related]
18. The effects of inducible nitric oxide synthase inhibitor L-N6-(1-iminoethyl) lysine in gentamicin-induced acute tubular necrosis in rats.
Avdagić N; Nakas-Ićindić E; Rasić S; Hadzović-Dzuvo A; Zaciragić A; Valjevac A
Bosn J Basic Med Sci; 2007 Nov; 7(4):345-51. PubMed ID: 18039194
[TBL] [Abstract][Full Text] [Related]
19. Identification of N-iminoethyl-L-ornithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells.
McCall TB; Feelisch M; Palmer RM; Moncada S
Br J Pharmacol; 1991 Jan; 102(1):234-8. PubMed ID: 1710525
[TBL] [Abstract][Full Text] [Related]
20. Effect of L-N6-(1-iminoethyl)-lysine, an inducible nitric oxide synthase inhibitor, on murine immune response induced by Actinobacillus actinomycetemcomitans lipopolysaccharide.
Sosroseno W; Musa M; Ravichandran M; Fikri Ibrahim M; Bird PS; Seymour GJ
J Periodontal Res; 2007 Apr; 42(2):124-30. PubMed ID: 17305870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
